Navigation Links
Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Date:4/8/2013

bone marrow. This is important because existing therapies often fail to effectively eliminate cancer cells in these tissue sites. Targeted therapy for CLL is becoming a reality, and this new approach may greatly improve the lives of patients with this disease."

The study also evaluated in vivo effects of ibrutinib using blood and tissue samples collected before and during treatment. Ibrutinib demonstrated rapid and sustained disease control in blood, lymph nodes, spleen and bone marrow. After 6 months, 95 percent of patients experienced a reduction in lymph node size and all showed reduction in spleen enlargement, with a median reduction of 55 percent. In 26 patients, for whom a bone marrow biopsy was done, tumor infiltration decreased by 82 percent.

The Progression Free Survival probability for these patients at 12 months was estimated to be 94 percent. Most adverse events were mild and manageable and included diarrhea, fatigue and rash, severe events occurred in less than 13 percent of patients. 

"We are very pleased with the continued research that is being demonstrated at AACR across 9 different presentations. These advances show the potential breadth of the ibrutinib program and provide further opportunities for us to pursue. We are grateful for the continued support of our collaborators, investigators, patients and shareholders," said Bob Duggan , CEO and chairman of the board.

Ibrutinib has been designated as a FDA Breakthrough Therapy in CLL patients with deletion 17p, based on data from completed Phase I/II clinical studies, where ibrutinib as a monotherapy was used to treat patients with this disease. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease, and may provide a substantial improvement over existing therapies for this indication.

About Chronic Lymphocytic Leukemia

CLL is the most common type of leukemia, a cancer of the whi
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22 2015 /CNW/ - The Taskforce representing Canada,s ... all the hard work that the Minister and Health Canada ... This program recognizes the needs of the thalidomide survivors, and ... a year, tax free, with annual adjustments for inflation. ... annual payments of $100,000 based on the severity of their ...
(Date:5/22/2015)... -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading developer, ... and cryopreservation freeze media and precision ... the "Company"), announced that the Company is scheduled to present ... Company is scheduled to present at the Conference at 1:30 ... Hyatt Hotel in New York City ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015  RegeneRx ... focused on tissue protection, repair and regeneration, today announced ... RegeneRx, is scheduled to present a corporate overview at ... will present at the SeeThruEquity 4 th Annual ... New York City at 11:00 am ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3
... 2011 Masimo (NASDAQ: ... of Health & Human Services (HHS) has added Critical ... as a national newborn screening standard.  In addition, the ... detection, published online in the Lancet (appearing ...
... Janssen Biotech, Inc. announced today that the U.S. ... for the treatment of moderately to severely active ulcerative ... inadequate response to conventional therapy.  This marks the 16th ... for the anti-tumor necrosis factor (TNF)-alpha in the treatment ...
Cached Medicine Technology:U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 2U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 3U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 4U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 5U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 6U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 7U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 8U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 9U.S. Health & Human Services Makes Critical Congenital Heart Defect Screening Using Motion-Tolerant Pulse Oximetry a Nationwide Newborn Screening Standard 10REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 2REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 3REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 4REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 5REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 6REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 7REMICADE® Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative Colitis 8
(Date:5/24/2015)... (PRWEB) May 24, 2015 EnviroLeather™ ... launches “InkGard™ Plus” – a classic, rugged leather ... polymer allowing difficult stains, including ink, to be ... different colors suitable for corporate, healthcare, hospitality and ... line with EnviroLeather’s goal of developing products that ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 ... System CEO - The students ... honored at the fourth annual A ... 15 at Geneva National in Lake ... ,     -Badger High School,         Jonathan Alfonso, ...
(Date:5/23/2015)... May 23, 2015 With the implementation ... are finding it increasingly difficult to provide their employees ... to provide adequate insurance for employees stand to face ... such an integral part of a business’s success or ... for businesses, Online USA Doctors has created a varying ...
(Date:5/23/2015)... Janesville, WI (PRWEB) May 23, 2015 ... Mercy Acceleration at the Sports Medicine and Rehabilitation Center, ... running clinic program, Mondays, June 1-July 20, 5:30-6:30 pm. ... MS, USAT coach, and Laurie Finke, RN, BSN, who ... flexibility exercises, education on nutrition, running mechanics and show ...
(Date:5/22/2015)... Francisco, CA (PRWEB) May 22, 2015 ... hosting two exciting events in June. They will hold ... Professional Doctorate and a two-day class on Classical Chinese ... p.m. June 3, Dr. Steve Given, the Dean of ... will discuss the new First Professional Doctorate program. ACTCM ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2
... TORONTO, Feb. 12 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. ... the company,s,business direction in light of the recent decision ... to the FDA, PreMD today filed a request ... accordance with the following Code of Federal Regulations 21,CFR ...
... Asoyia-MO is the first and only soybean oil to provide ... fats per serving, and light, clean taste., IOWA CITY, ... a new product that not only meets the increasing,consumer demand ... of stability and neutral taste so important to food processors., ...
... individuals or families may have underlying speech deficits ... a personal or family history of learning disabilities may ... dementia that causes them to lose language abilities as ... The condition, known as primary progressive aphasia, causes language ...
... Comprehensive Account of Global Trends, Progress and ... with Response Planning, ANNAPOLIS, Md., Feb. 12 ... global intelligence and business resiliency services,today announced the ... and,Pandemic Planning. Created by iJET,s health intelligence team, ...
... and American Heart Association Join Forces to,Educate, ... Health, CHICAGO, Feb. 12 A recent ... Heart,Association found that, among African-Americans, two out of ... and two out of,five (40 percent) expressed concern ...
... Hutchinson - Named President and CEO of Prematics(TM) - ... Advancing Physician Adoption of Electronic Prescribing, BETHESDA, ... named Kevin Hutchinson, one of the nation,s most respected ... chief,executive officer of SureScripts, to lead the company,s next ...
Cached Medicine News:Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 2Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 3Health News:Asoyia Announces New Mid Oleic Ultra Low Lin Soybean Oil 2Health News:Learning Disabilities May Presage Later Language Problems 2Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 2Health News:iJET Unveils 2007 Year-in-Review Report on Avian Influenza and Pandemic Planning 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 2Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 3Health News:New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health 4Health News:Founding CEOS of SureScripts(R) and RxHub(R) Join Forces to Deliver Clinical Information Technology Services to Physician Practices 2Health News:Founding CEOS of SureScripts(R) and RxHub(R) Join Forces to Deliver Clinical Information Technology Services to Physician Practices 3
... Profile Ergonomic Design for Neurosurgery. ... offers rigid working channel scopes ... The rigid scope body facilitates ... the target. The steerable tip ...
... Ethisorb Dura Patch is a synthetic absorbable ... and. spinalis defects. Ethisorb Dura Patch is pliable, ... cut to the desired shape, care must be ... violet dyed, PDS foil covered side is oriented ...
... patch, Duragen is a matrix for ... handles and conforms similar to normal ... matrix for dural closure. Remarkable onlay ... defects. Fully resorbed following complete tissue ...
Elmed electrosurgical systems for major surgery....
Medicine Products: